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Serum Leukotriene Metabolism and Type I Hypersensitivity
Reactions in Different Animal
Director: Dr. George L. Card
The peptidoleukotrienes, leukotriene C4, leukotriene D4
and leukotriene E4/ (LTC4, LTD4, and LTE4) which are products
of the 5-lipoxygenase pathway of arachidonic acid
metabolism, play important roles in mediating
hypersensitivity reactions. LTC4 is the primary leukotriene
released from stimulated cells. A transpeptidase activity
converts LTC4 to LTD4, which is subsequently converted to
LTE4 bya dipeptidase activity. LTC4 metabolism was studied
in human, mouse, guineapig, rabbit, horse and cow sera.
LTD4 is the most potent of the peptidoleukotrienes. The
relative amounts of LTD4 present after specific periods of
incubation was compared in the sera of different species,
using tritium labelled LTC4 (3H-LTC4) After specific
incubation time, the lipids were extracted from the serum,
and the leukotrienes separated by Reverse Phase High
Pressure Liquid Chromatography. The leukotrienes in the
different fractions were quantitated based on the
radioactivity in the corresponding fractions. The profile
of metabolism was different for each species in that the
rate of formation of LTD4 (transpeptidase activity) and the
rate of LTD4 metabolism (dipeptidase activity) varied in the
different species. On the basis of these two enzymatic
activities, the different animal species tested could be
divided into four categories;(1)those with high
transpeptidase and dipeptidase activity, which would result
in large amount of LTD4 accumulation initially, with a rapid
decline, as in horse and cow:(2)those with low activity of
transpeptidase and dipeptidase, resulting in accumulation of
formed LTD4, as in guineapig;(3)those with high
transpeptidase activity and a low dipeptidase activity which
would result in accumulation of large amounts of LTD4, as in
humans;(4)those with low transpeptidase and high dipeptidase
activitywhich results in very low or no accumulation of LTD4
as in mouse. The results show a relationship between the
relative amounts of LTD4 observed and the manifestation of
Type I hypersensitivity in the different species.
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INTRODUCTION

Arachidonic acid (a 20-C polyunsaturated fatty acid),
is a 5,8,11/14-eicosatetraenoic acid.

Arachidonic acid (AA)

and its metabolites are known to play important roles in
mediating hypersensitivity reactions like bronchial asthma,
allergic rhinitis and psoriasis (24,32).
Arachidonic acid is usually present in membrane
phospholipids (phosphatidyl choline, phosphatidyl inositol,
etc.) esterified primarily to the second carbon (C-2)
position.

Release of AA from the C-2 position is mediated

by different types of stimuli, which can be physiological or
pathological (64).

Hormones like angiotensin, bradykinin,

epinephrine, antigen-antibody complexes etc. are
physiological stimuli, whereas ischaemia, mechanical damage,
membrane-active venoms (like mellitin from bee venom), Ca2+
ionphores (A23187), phorbol esters etc. are pathological
stimuli.

The membrane AA is released by the effect of two

phospholipase: phospholipase C, which is specific for
phosphatidyl inositol, and phospholipase A2, which is
specific for phosphatidyl choline (Fig. 1).

In general, all

stimuli lead to changes in cell membrane, which lead to
transport of ions across the membrane, especially a flow of
Ca2+ ions from the extracellular to the intracellular
1
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Fig. 1. Mechanisms involved in release of arachidonic acid.
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compartment.

The resulting increased intracellular Ca2+

concentration stimulate the cytoplasmic phospholipase C,
which acts on phosphatidyl inositol to give
inositoltriphosphate (IP3) and diacylglyceride (DAG).

DAG

is acted upon by other lipases to a monoacylglyceride and
AA.

IP3 induces further Ca2+ mobilization from the

endoplasmic reticulum to the cytoplasm,
activates phospholipase C.

and this further

The DAG which is not converted

to monoglyceride, stimulates other enzymes.

Protein kinase

C (PKC) is a major enzyme activated by DAG.

PKC

phosphorylates a phospholipase A2 inhibitory protein.

This

causes activation of phospholipase A2, which cleaves AA from
phosphatidyl choline (64).
half life.

The released AA has a very short

It is either metabolized, by a cyclooxygenase or

a lipoxygenase pathway, or is reincorporated into the
membrane phospholipids.

Very small amounts of AA are found

in the free fatty acid pool.

This low level is thought to

be maintained by the action of an acyl-CoA transferase,
which esterifies arachidonyl-CoA into phospholipids (25).
The metabolism of AA by the lipoxygenase and the
cyclooxygenase pathways are together known as the
arachidonic acid

cascade (Fig. 2).

Metabolism by the

cyclooxygenase pathway leads to the formation of
prostaglandins (PGs).

The first PG to be formed is PG-G2.

This is converted to PG-H2 from which other PGs and
thromboxanes are formed.

4
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Fig. 2. The arachidonic acid cascade.
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The lipoxygenase pathways involve metabolism by 5-, 15and 12-lipoxygenases.

Lipoxins are produced by the 15-

lipoxygenase pathway, and hydroxy eicosatetraenoic acids
(HETES) are produced by the 12-lipoxygenase pathway.
The 5-lipoxygenase pathway converts AA to 5hydroperoxy,6,8,11,14 eicosatetraenoic acid (5-HPETE).

5-

HPETE can then undergo enzymatic conversion to 5-HETE or to
5,15,diHETE.

Leukotriene A4 (LTA4) is formed from 5-HPETE

by an LTA4 synthase.

LTA4 is very unstable.

The action of

an LTA4 hydrolase converts LTA4 to LTB4, which is relatively
stable.

LTB4 can also be formed from 5-HETE, in the

presence of cytochrome P-450 (64).

Conversion of LTB4 to

its wOJ -metabolites by Polymorphonuclear cells (PMNs) has
been reported.

20-carboxy LTB4 and 20-hydroxy LTB4 are the

products of Co -oxidation.
LTA4 undergoes enzymatic conversion to LTC4 by the
action of a glutathione-S-transferase, which is specific for
LTA4.

Addition of a glutathione residue to the C-6 position

by a sulfo-ether linkage, leads to the formation of LTC4,
which is the first peptidoleukotriene to be formed.

LTC4,

along with its metabolites, LTD4 and LTE4 were formerly
known as the Slow Reacting Substances of Anaphylaxis
(SRS-A),
1930

Although SRS-A has been identified as early as

it was only in 1980 that it was found to be a mixture

of peptidoleukotriens (7).
is LTD4 (48).

The main component of the SRS-A

The name leukotriene refers to the

6

observation that they were seen to be released by
leukocytes, and had three conjugated double bonds.
LTC4 is the form in which the peptidoleukotrienes are
released into the extracellular medium.

LTC4 is converted

to LTD4 by transpeptidase reaction (64) that removes the
glutamate

from the glutathione residue.

LTD4 is further

converted to LTE4 by a dipeptidase activity (64), which
cleaves the glycine from LTD4.
Several cell types are involved in the release of
leukotrienes.
(57,65).

LTB4 is released primarily from the PMNs

It is also released from

parenchyma (68).

bronchi and lung

LTC4, on the other hand, is released

predominantly from the

eosinophils (57,65), mast cells,

alveolar macrophages (24),and in lung, parenchymal
tissue (68).
The metabolism of the peptidoleukotrienes has been
studied in detail, both in vivo, and in vitro.

In-vitro

studies, showed conversion of LTC4 to LTD4 in Rat
Leukemia (RBL-1) cells (42).

Basophil

The conversion of LTD4 to LTE4

was also first detected in RBL-1 cells (43).

In fact, the

SRS-A was first shown to be a metabolite of AA in RBL-1
cells (27).

The metabolism of leukotrienes has also been

studied in human plasma (1,31), and in the supernatant of
PMNs (51).

The transpeptidase activity responsible for the

formation of LTD4

is released by PMNs, as seen by the

formation of LTD4 from LTC4 in the supernatant of a

7
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Fig. 3. Metabolism of the peptidoleukotrienes.
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suspension of PMNs (51).

The transpeptidase activity and

dipeptidase activity were seen to be released from PMNs
following immunological as well as nonimmunological stimuli
(54).

The transpeptidase activity was seen to be localized

in the microsomal fraction of PMNs, by subcellular
fractionation (51).

This activity has also been detected in

plasma (1), in the supernatant of alveolar macrophages,
(15), and in the parenchyma of human and guinea pig lung
tissue (53,54).

The transpeptidase activity that converts

LTC4 to LTD4 is thought to be due to a Y*-glutamyl
transferase, as glutamate was seen to be a substrate for
this enzyme (23) and since inhibitors of Y-glutamyl
transferase (L-serine borate, avicin) (43) inhibited the
formation of LTD4.
Other than conversion to LTD4, LTC4 can also undergo
oxidative metabolism to biologically inactive products (33).
This reaction was seen to take place during the respiratory
burst in PMNs. Sulfoxides of LTC4, like LTC4 chlorsulfonium
ion, are metabolites of this oxidative metabolism.
LTD4 is converted to LTE4 by a dipeptidase activity
(64), which was associated with specific granules of PMNs
(34 ), and plasma membrane of RBL-1 cells (51).

This

activity is present in alveolar macrophages, and in lung
parenchyma, as shown by the presence of LTE4 in these
tissues following antigen challenge (17).
dipeptidase inhibitor (43).

L-cysteine is a

The dipeptidase activity also

9

requires the presence of divalent cations. Substances like
L-cysteine and dithiothreotol, which bind divalent cations,
decreased the dipeptidase activity, which was subsequently
restored by the addition of Co2+, Zn2+, or Mn2+ into the
system (52).
LTE4 is relatively stable.

It can undergo further

conversion to N-acetyl LTE4 in the presence of acetyl Co-A.
This has been shown by the use of

14C-Acetyl

CO-A (23) .

LTE4

and N-acetyl LTE4 are the main excretory metabolites of
peptidoleukotriene metabolism in man and other mammalian
species (6,60).

N-acetyl LTE4 can also be converted to 20-

carboxy N-acetyl LTE4 and 20-hydroxy N-acetyl LTE4 (23).
Addition of a glutamate residue to LTE4 by a

Y-glutamyl

transferase leads to the formation of LTF4, which is a Vglutamyl-cysteinyl leukotriene(23).
Other than arachidonic acid, trienoic and pentaenoic
acids were also seen to be metabolized to
peptidoleukotrienes LTC3 and LTCS, as seen by the presence
of LTE3 and LTES in RBL-1 cells.

These leukotrienes, with 3

or 5 double bonds, were seen to cross react with anti-LTC4
antibodies.

The biological activity and enzyme

specificities of these leukotrienes were seen to be similar
to that of the leukotrienes with four double bonds (43).
The biological activities of the different leukotrienes
have been described (55).
activity.

LTB4 is mainly chemotactic in

It facilitates migration of all leukocytes, but
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the PMNs are mainly affected.
microvascular permeability.

LTB4 also increases

The peptidoleukotrienes, also

referred to as the cysteinyl leukotrienes, have a smooth
muscle constrictor effect, and thus induce bronchospasm.
LTC4, LTD4 and LTE4 are reported to be

100 to 1, 000 times as

potent as histamine, on a molar basis (48,55).

Other than

their direct constrictor effect on airway smooth muscle,
they can also potentiate the action of other inflammatory
mediators.

LTC4 and LTD4 increase microvascular

permeability and mucous secretion in bronchioles.

These

activities suggest that the cysteinyl leukotrienes are the
major mediators of

type I hypersensitivity reactions like

bronchial asthma, allergic rhinitis and anaphylactic shock.
Four types of hypersensitivity reactions are recognized:
Type I, Type II, Type III and Type IV (64).

These are

inflammatory reactions, mediated by the release of
pharmacologically active substances like histamine and
leukotrienes, from specific cell types, following antigenantibody reactions.

The Type I reactions are more acute,

and cause more discomfort.

This type of reaction is

referred to as immediate hypersensitivity reaction, allergy
or anaphylaxis.

Antigen-antibody reactions cause release of

AA and its metabolites directly from cell membranes of mast
cells.

AA metabolites, like leukotrienes, which are

mediators of hypersensitivity reactions are also released
directly by eosinophils, which are attracted to the site of
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the reaction by chemotactic substances released by mast
cells.

These substances are called eosinophil chemotactic

substances of anaphylaxis (ECF-A).

The symptoms of Type I

hypersensitivity can be attributed to the sum total of all
the above factors.

Bronchial asthma, which is a Type I

hypersensitivity reaction , is characterized by severe
prolonged bronchoconstriction and airway obstruction,
of which are due to the release of these mediators.

both

In

fact, several workers have reported the presence of elevated
plasma levels of cysteinyl leukotrienes
asthmatic attack (40,56,68).

during the

Eosinophils from asthmatic

individuals have been reported to produce larger amounts of
LTC4 than those from normal individuals (59).

The Type II

hypersensitivity reaction results in cell destruction due to
antigen-antibody reactions.
fall into this group.

Blood group incompatibilities

The Arthus reaction, acute and

chronic serum sickness which come under the Type III
hypersensitivity reaction are produced by localized tissue
damage due to deposition of immune complexes.

Type IV

hypersensitivity reactions are cell mediated reactions, in
response to localized injection of antigen.

It is mediated

through lymphocytes and is called delayed hypersensitivity
reaction (DHR).
The metabolism of LTB4 in human blood has been
studied (71).

It was seen that LTB4 slowly undergoes co-

oxidation, to 20-hydroxy and 20-carboxy LTB4.

There was no

difference in the rate of metabolism between normal and
asthmatic individuals, suggesting that this pathway may not
influence the outcome in a hypersensitivity state.
The cysteinyl or peptidoleukotrienes

have been

implicated in a wide variety of hypersensitivity disorders
eg., bronchial asthma (56,59), psoriasis (10) and allergic
rhinitis (67).

In an allergic condition, the eosinophils,

which release the peptidoleukotrienes, are thought to be
attracted to the tissue by the LTB4 released by the PMNs
(57).

LTC4 is the form in which the SRS-A is released from

stimulated cells.

Therefore, the high levels of LTD4

detected in the plasma of

individuals during the asthmatic

attack (40), and the LTD4 and LTE4 seen following antigen
challenge in human (17) and guinea pig (53) lung, must be
due to the presence of metabolizing enzymes released into
the medium.

The release of these enzymes following antigen

challenge have been shown by several workers (15).

An

elevated amount of leukotriene release has been reported
from the lung (14), and stimulated blood cells (eosinophils)
of individuals with allergic asthma and chronic bronchial
asthma (59).

This observation suggests that an increased

release of leukotrienes might be the factor that predisposes
these individuals to the development of hypersensitivty
reactions.
A comparison of the urinary LTE4 levels in normal and
atopic individuals after antigen challenge, and in asthmatic
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individuals during the asthmatic attack, showed that
although the LTE4 levels were elevated in atopic individuals
following antigen challenge, they were not elevated in
individuals during the acute asthmatic attack, or in
individuals having a severe episode of allergic rhinitis
(60).

These results suggest

that if an increased release

of LTs does occur during an acute asthmatic attack,

there

might be an alteration in the further metabolism of these
leukotrienes to a biologically less active and excretable
form,

as increased levels were not detected in the urine

during the acute attack.
Bronchial asthma is an anaphylactic reaction.
Therefore , anaphylaxis induced in animal models should
serve as an excellent model to study the role of leukotriene
metabolism in bronchial asthma, and in hypersensitivity
reactions as a whole.

Although the phenomenon of

hypersensitivity was observed in 1839 by Magendie, in
rabbits, it was Richet, in 1902, who first recognized the
reaction in dogs and named it "anaphylaxis" meaning "without
protection" (50).

Theobald Smith, in 1905, noted the ease

with which guinea pigs developed anaphylaxis as compared to
other animals (50).

Thus guinea pigs became the

experimental animal of choice to elicit the anaphylactic
reaction in future experiments.

The symptoms of anaphylaxis

in guinea pigs were seen to resemble those in humans.
bronchoconstriction observed, was similar to that in

The
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bronchial asthma (Burson, 1911, as quoted by Alexander,
1926) (3).

Later, Chase reported that it was possible to

elicit the cutaneous anaphylactic reaction in guinea pigs,
just as in humans.

Experiments conducted by Rabat in 1942

(28), indicated that very small amounts of antigen was
sufficient to induce anaphylaxis in guinea pigs.

Isolated

guinea pig smooth muscle was also found to have the same
amount of responsiveness to antigen as the intact animal.
The amount of antigen required to produce fatal anaphylaxis
was also found to be very small (29).

Guinea pig smooth

muscle was used as early as 1926 to elicit the Schultz-Dale
reaction, in order to elicit the sensitivity of smooth
muscle to antigen.

This experiment is used widely, to study

the effect of several mediators of anaphylaxis, because the
symptoms of anaphylaxis are due to smooth muscle
constriction.

In many recent reports, the guinea pig has

been used to elicit the anaphylactic reaction, in order to
study the role of leukotrienes in anaphylaxis (30,53,62,63).
Release of leukotrienes from trachea (53) and lung (62) of
guinea pig following antigen challenge has been reported.
These findings are also similar to reports of identical
experiments conducted on human lung tissue (54).
The mechanism of anaphylaxis was studied in mice by
Weisser and coworkers in 1941 (69).

A series of experiments

were conducted to determine the susceptibility of mice to
develop anaphylaxis after active and passive sensitization.

15

The mice responded with little or no signs of anaphylaxis,
and none showed fatal anaphylaxis.

Hours after unilateral

adrenalectomy, two mice had fatal shock, while the majority
of animals died of shock after bilateral adrenalectomy.
Sobey and Adams, in 1959, used a score, called anaphylactic
score, to study the anaphylactic reaction in a batch of
mother and daughter mice (58).

This was based on symptoms

like itching and decreased activity.

A wide variation was

found in the anaphylactic score in different mice.

Based on

these observations, they concluded that the anaphylactic
potential of a mouse was determined by that

of its mother

and that this potential was under genetic control.

The

development of passive cutaneous anaphylaxis (PCA) was also
found to be much slower in mice than in guinea pigs, and
required a much larger dose of antigen (45). These findings
were later supported by Levy in 1964 (35), who developed a
technique to elicit PCA and reverse passive Arthus reactions
simultaneously.

A difference was noticed between three

animal species.

The mouse was found to be least sensitive

to these cutaneous reactions, showing only a mild reaction
to undiluted antigen.

The rat was about 10 times more

sensitive than the mouse, responding to 1/10 dilution,
whereas the guinea pig was 1,000 times more sensitive than
the mouse, since anaphylaxis was induced by a
dilution of the antigen.

1/1,000

The difficulty in eliciting

anaphylaxis and fatal shock

in rats has also been described
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(49).

Bilateral adrenalectomy was necessary to induce signs

of fatal shock.

The difficulty in inducing the Arthus

phenomenon in rats, as compared to guinea pigs and rabbits
has also been described (41).
The development of anaphylaxis in rabbits has been
described as early as 1911 (Auer, as quoted by Coca in 1919)
(16).

The anaphylactic reaction in rabbits does not

resemble that in humans.

Although during anaphylaxis

symptoms of respiratory distress were present,
bronchoconstriction was not seen in rabbits.

The cause of

death in fatal shock was cardiac failure, due to increased
pulmonary arterial pressure, as opposed to bronchiolar spasm
in guinea pigs (50).

This is explained by the fact that in

rabbit, the pulmonary artery has a well developed smooth
muscle layer, while the bronchiolar musculature does not.
Manwaring used rabbit smooth muscle to study the response to
antigens (36).

It was found that although the animal

developed fatal shock, smooth muscle contraction, as
recorded by rise in intra cystic pressure, was very rare in
rabbits, when compared to guinea pigs. Recent experiments
have shown that LTC4 and LTD4 were seen to produce strong
contraction in guinea pig lung parenchyma, while in rat and
rabbit lung parenchyma, the dose required to produce a
similar contraction was 3-4 fold higher (47).
Horse and cattle anaphylaxis are noted to have some
similarity to human reactions (50).

Dyspnoea, increased
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peristalsis, and sweating are the main symptoms.

In horses,

the anaphylactic response is characterized by acute
hypotension, followed by increased pulmonary arterial
pressure and respiratory distress within 8-12 minutes.

In

cattle, similar symptoms are described, with severe
reactions taking 15-20 minutes to manifest themselves.

In

both species death is reported to occur in 2-5 minutes (8).
In the calf, abdominal distension is a marked feature.

This

was explained by the presence of a strong smooth muscle
layer in the stomach compartments (50).
It is clear from the above data that a difference
exists in the susceptibility of different species to develop
anaphylaxis.

The role of the peptidoleukotrienes

anaphylaxis has also been established.

in

Studies have been

done on in-vivo LTC metabolism in different species and
differences in the metabolite that accumulates after
specific periods of time have been reported (4, 23,44).

In

vitro studies have been done to study the products of
metabolism and the comparative uptake of LTC by isolated
organs and cells (23).

The results of these studies showed

a differential uptake by different organs.
LTC4 has been studied in human plasma.

Metabolism of

Although human

plasma was seen to convert LTC4 to LTD4 and LTE4 (1,31), LTD
was not seen in the mouse or guinea pig tissues in in-vivo
studies using LTC (4,22).

In vivo studies on the metabolism

of leukotrienes in different species has also shown that the
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form in which the leukotrienes are excreted differed with
the species.

In humans, LTE4 was the main excretory

metabolite of LTC4 metabolism (60,66), while in monkeys, Nacetyl LTE4 was the form in which the peptidoleukotrienes
were excreted (6).
metabolite (44).

In rats, N-acetyl LTE4 was the main
Considering these observations, it seemed

likely that the profile of LTC4 metabolism in the serum of
these animal species would differ.

This assumption was

supported by observations made during our preliminary
experiments using human and mouse serum (11).

The profile

of LTC4 metabolism in mouse serum was seen to be very
different from that in human serum, in that, after a
specific incubation period, no LTD4 was detected in mouse
serum; most of the leukotriene detected was in the form of
LTC4, with small amounts present in the LTE4 fraction.
Under the same conditions, human serum showed presence of
significant amounts of LTD4 and LTE4, with very little LTC4.
Since LTD4 is known to be the most potent biologically among
the peptidoleukotrienes, this observation correlated with
the present knowledge concerning the susceptibility to the
development of anaphylaxis in mice and humans.
This study is intended to compare the profiles in LTC4
and LTD4 metabolism in human, mouse, rabbit, guinea pig,
horse, cow and fetal calf sera.

THESIS OBJECTIVES: The role of peptidoleukotrienes in
anaphylaxis has been established. A species specific
susceptibility to develop anaphylaxis has also been
described. The main objectives of this study are to
determine 1) if a species specific difference exists in the
metabolic profile of LTC4, which is the form in which the
peptidoleukotrienes are released, and 2) if the anaphylactic
susceptibility of an animal correlates with the profile of
its LTC4 metabolism.

MATERIALS AND METHODS

Collection of Animal Blood and Sera

Human blood collected from normal human volunteers,
with no history of asthma or other allergic manifestations,
was drawn from the cubital vein into heparin free
vacutainers.

The source of mouse blood was Balb-C mice in

all experiments except the last one, in which the strain of
mice used was Swiss Webster (SW) mice. The blood collected
from several mice by way of the brachial artery, or the
guillotine method was pooled.

For rabbit blood, the New

Zealand White strain of rabbit was used.

Blood was

collected by puncturing the marginal vein of the ear lobe
with a 22 gauge needle.

Guinea pig blood was collected from

Duncan Hartley guinea pigs by cardiac puncture.

The horse,

as well as the cow were bled from the jugular vein into
heparin free vacutainers.

Fetal Bovine Serum (FBS) was

purchased from Sigma Chemicals (Sigma Culture Reagents).
In all cases except with mice and rabbit, the blood was
drawn into vacutainers.

Pooled mouse

blood was collected

in centrifuge tubes, and rabbit blood from the marginal vein
of the ear lobe was allowed to flow into the centrifuge
tubes.
Clotting of Blood:

The blood was incubated at room temperature until
20

clotting occurred, (usually 1 hour to 90 minutes), and
centrifuged using a clinical centrifuge (International
Equipment)

for 20 minutes at room temperature.

The serum

that was not used was transferred to vials and stored at
-70°C.
Since changes in activity of enzymes were noticed using
stored serum, a standard method was chosen for clotting
procedures in order to ensure that all samples were being
treated under the same conditions.

The blood collected into

heparin free vacutainers or conical centrifuge tubes was
placed on ice until they could be placed in a 30°C water
bath.

Clotting was allowed to take place at 30°C for one

hour.

The clotted blood was centrifuged at 2,000 rpm for

ten minutes at 4°C.
4°C until use.

The serum collected was maintained at

The serum that was not used immediately was

stored in vials of 1 ml each at -70°C.

The glassware,

syringes, and all other instruments used were sterilized
prior to bleeding.
Enzyme Assays:

Substrates:

Synthetic unlabeled leukotrienes LTC4,

LTD4, and LTE4 were purchased from Cayman Chemicals, Ann
Arbor, Michigan.

The preparations contained 0.1 mg/ml of

leukotrienes, dissolved in 0.25 ml of 1:1 ethanol/PBS.
Tritium labeled leukotrienes were purchased from DuPont-NEN
products.

The specific radioactivity of the leukotrienes

was 39.3 Ci/m mol, (2.2 X 106 dpm//1!) in 0.5 ml of 50%
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ethanol, 0.01 M 2K2P04, at a pH of 6.8.
Unlabeled leukotriene (160 p mols) mixed with 22,000
dpm of tritium labeled leukotrienes was used as a substrate.
Hartmann's Solution (Lactated Ringer Solution):
Potassium chloride
- 0.03
Sodium chloride
- 0.6
Calcium chloride
- 0.02
Sodium Lactate
- 0.31
Made up to 100 ml using dd H20.

gms
gms
gms
gms

Assay Mixture:

The assay mixture consisted of 100 ft-l of undiluted
serum (unless otherwise mentioned).

A stock solution of

the leukotriene mix was made up in Hartmann's solution
containing 1% Triton X-100

so that each sample received 160

pmols (22,000 dpm) of leukotriene and 25 /*1 of 1% Triton X100.

This gave an effective dilution of 0.1% Triton X-100

in the assay mixture), the volume of which was made up to
250 ul with Hartmann's solution.

Incubation was carried out

at 37°C, for specific time periods. The reaction was stopped
by the addition of two volumes of methanol at -20°C,
containing butylated hydroxy toluene (BHT) as an
antioxidant.

After the addition of methanol, the samples

were mixed well, and kept at -70°C for at least one hour
prior to centrifugation, in order to precipitate proteins.
The mixture was then centrifuged at 2,000 rpm for ten
minutes at 4°C.

The supernatant was transferred to conical

centrifuge tubes, evaporated to dryness under vacuum at
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40°C.

Samples were stored at -70°C until HPLC analysis.

The glassware used for the assays were siliconized using
Sigmacote (Sigma Chemicals), in order to prevent adherence
of LTs to the surfaces, and hence loss of the leukotrienes
during extraction.
RBL-1 Cells:

Rat Basophilic leukaemia cells were purchased from
American Tissue Culture Collection.

The cells were

maintained in Iscove's modified Dulbecco's medium containing
L-glutamine, in the presence of 10% fetal calf serum.
Stimulation of RBL-1 Cells:

RBL-1 cells were washed twice with 1 ml of serum free
media.

The cells were resuspended in Phosphate Buffered

Saline (PBS, Sigma Diagnostics) at a concentration of
approximately 106/ml.

The cells were stimulated using

lipopolysaccharide (LPS) purchased from Ribi Immunochem
10 ngms/ml, and calcium ionophore (A-23187, Sigma Chemicals)
10 ngms/ml, for 30 minutes at 37°C in the presence of 5 mM
calcium chloride (2) .

After stimulation, leukotrienes were

added, and the samples incubated for 30 minutes at 37°C
before lipids were extracted.

Lipid Extraction:

Modified Bligh and Dyer procedure:

This procedure was

used in preliminary experiments using RBL-1 cells.

After

the specific incubation time, the cells were pelleted by
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centrifugation in a clinical centrifuge.

To the

supernatant, two volumes of methanol were added,

mixed

well, and the proteins allowed to precipitate at -70°C.

The

protein precipitate was pelleted by centrifugation at 2,000
rpm at 4°C, and to the supernatant, were added two volumes
of chloroform, mixed well for one minute, centrifuged, and
the chloroform fraction was separated by centrifugation in a
clinical centrifuge.

The chloroform fraction was collected

in a conical centrifuge tube, evaporated to dryness under
vacuum, and stored at -70°C until analyzed by reverse phasehigh pressure liquid chromatography (RP-HPLC).
Sep-Pak procedure:

After protein precipitation using two

volumes of methanol, the supernatant was made up to contain
20% methanol, using sodium phosphate buffer (0.1 M, pH 7.4).
The sample was run through a C-18 cartridge (Bakerbond spe,
J.T. Baker Inc.), pre-washed with 20 ml methanol and 20 ml
water.

The cartridge was then washed with 5 ml of 20%

methanol in sodium phosphate buffer, followed by 5 ml of
water.

The leukotrienes in the cartridge were then eluted

with 3 ml of 80% methanol in distilled water.

This eluent

was dried down, and analyzed by RP-HPLC.
Direct evaporation technique:

The Sep-Pak procedure

resulted in low recovery of leukotrienes in the different
fractions.

So we developed a method, in which direct

evaporation of the supernatant, after protein precipitation,
was done.

The evaporated sample was stored at -70°C, until
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it was resuspended in solvent and analyzed by RP-HPLC.

This

procedure involved minimal loss of radioactivity in
different fractions, and less loss by adherence to
glassware.

The presence of other substances with UV

absorbance at 280 nm did not interfere with the analysis,
since calculation were based only on radioactivity in
different fractions.

Reverse Phase High Pressure Liquid Chromatography (RP-HPLC)
Analysis

Solvent:

The solvent system used was: acetonitrile:

methanol: water: acetic acid
V/V/V/V).

(1280 / 800 / 1916 / 4,

The pH was adjusted to 5.5 using ammonium

hydroxide (5).

The samples that had been evaporated to

dryness were resuspended in 250 pi of solvent and injected
into a Nucleosil 5-C18 (25 x 4.6) column (Phenomenex),
maintaining a flow rate of 1.0 ml/min.
was applied.

A pressure of 60 psi

The sample was eluted from the column, for a

total time of 25 minutes.

The column was then rinsed with

100% methanol for 15 minutes.

The solvent was then allowed

to run through the column for 15 minutes to equilibrate the
column before the next sample was injected.
peptidoleukotrienes have a max at

The

279 nm (38).

The elution times of the different leukotrienes were
marked (according to UV absorption peaks at 280 nm) using
standard LTC4, LTD4, LTE4, LTF4 and N-acetyl LTE4.

In initial
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experiments, to quantify the relative amounts of
leukotrienes present after each assay, the UV absorption
peaks of the different leukotrienes at the characteristic
elution times were matched with the radioactivity in the
corresponding fractions.

The fractions were collected using

a Gibson model 203 micro fraction collector.

The

radioactivity in the fractions were then determined in a
Beckman 7500 scintillation counter.

The different

leukotrienes were quantitated based on the percentage of
total recovered radioactivity in each peak.

In later

experiments, a Flo-one Beta In-line radioactive flow
detector (Radiomatic) was used in which the UV absorption,
as well as the radioactivity of the eluted leukotrienes were
simultaneously displayed.

RESULTS:

Evaluation of analytical procedures

In the initial experiments with RBL-1 cells, a modified
Bligh and Dyer technique of lipid extraction was compared to
a technique using C-18 cartridges (Sep-Pak) (26) and one
involving a direct evaporation of the methanol fraction
after protein precipitation.

The recovery of the

leukotrienes by the Bligh and Dyer technique was 58.13%
(S.D. 10.43,n=10), while the recovery using C-18 cartridges
was 71.48% (S.D. 12.6,n=10), and that by the direct
evaporation technique was

89.52% (S.D. 8.61,n=20).

The

elution profile for a mixture of the different leukotrienes
is by RP-HPLC using the solvent system previously described,
is shown in Fig. 4.

Leukotriene Metabolism in RBL-1

Cells

Initial experiments to study conversion of 3H-LTC4,
standardization of lipid extraction and enzyme assay
procedures were done using RBL-1 cells.

RBL-1 cells,

stimulated by bacterial lipopolysaccharide, in the presence
of Ca2+ and A-23187 (calcium ionophore), were seen to
produce both

3H-LTD
4

and 3H-LTE„ from
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3H-LTC
4

(Fig. 5).
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Fig. 4. Relative elution times of standard leukotrienes LTC 4 , LTD 4/ LTE 4/ LTF 4 , and N-acetyl LTE 4 .by RP-HPLC
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Fig. 5. Metabolism of 3H-LTC4 in the supernatant of RBL- 1
cells. RBL-1 cells were resuspended to a
concentration of approximately 10 cells/ml and
stimulated with LPS and A 23187 (calcium
ionophore) in the presence of calcium. 1ml of the
supernatant was assayed for transpeptidase
activity and leukotrienes separated by RP-HPLC.
Radioactivity was calculated at elution times
corresponding to LTC4/ LTD4 and LTE4. Data is
expressed as percent radioactivity at different
elution times.
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Leukoreiene Metabolism in Human Serum

After procedures were standardized using RBL-1 cells,
human serum from a normal volunteer was used. Table I shows
the mean value and standard deviation of values obtained for
the percent conversion of LTC4 after 30 min. incubation and
for LTD4 after 15 min. incubation in six different serum
Conversion of 3H-LTC4 or 3H-LTD4 was not seen in

samples.

serum at 4°C, Hartmann's solution at 37°C, or following
denaturation of proteins(Fig.6,7).

3H-LTC
4

was converted to

3H-LTD4,

3H-LTE
4

as seen by the

which was then converted to

relative amounts of the different leukotrienes present after
15 and 30 minutes incubation (Fig.8).

The experiment was

repeated using serum from clotted blood, and plasma from
heparinized blood.

Heparinized blood showed a decrease in

the formation of LTE4, compared to serum (Fig. 9).
Thereafter, all experiments were conducted using serum.
The effect of storage of serum on the conversion of
LTC4 and LTD4 was studied using serum stored at 4°C, -20°C
and -70°C.

Prolonged storage resulted in significant loss

of the LTD4 conversion at 4°C, but not at -70°C (Fig. 10).
The experiments that followed were all done using fresh
serum, or serum that had been stored at -70°C immediately
after collection of blood.
The percent conversion of 3H-LTC4 to 3H-LTD4 and
3H-LTE
4

was seen to have a linear relationship with the

volume of serum used (Fig. 11).

The conversion of 3H-LTC4
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LTC4
Sample no.
1

LTD4

14.82

8.71

2

12.50

12.71

3

16.64

8.31

4

14.31

9.74

5

15.83

10.56

6

13.51

12.34

Mean

14 .60

10.39

S. D.

+1.51

+ 1.83

Table I.Mean and S.D. values for percent conversion of 3HLTC4 conversion (following 30 minutes incubation)
and 3H-LTD4 (following 15 minutes incubation) in
six serum samples.

Fig. 6. Chromatogram showing LTC4 profile after 90 minutes
incubation in (A) serum at 4°C (B) Hartmann's
solution at 37°C and (C) protein denatured serum.

Fig. 7. Chromatogram showing LTD4 profile after 45 minutes
incubation in (A) serum at 4° C (B) Hartmann's
solution at 37°C and (C) protein denatured serum.
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Fig. 8. 3H-LTC4 metabolism in human serum. 1 ml of fresh
human serum was incubated with 3H-LTC4 for 15 and
30 minutes. The reaction was stopped using 2
volumes of methanol. Leukotrienes were extracted
using C-18 cartridges. The recovered leukotrienes
were separated by RP-HPLC. Data shows percent
radioactivity at different elution times
corresponding to the different leukotrienes.
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Fig. 9. Comparison of3H-LTC4 metabolized in clotted and
heparinized blood, placed at 4 C for approximately
24 hours. Assay procedure was as described in
Figure 6. Figure shows relative amounts of LTC4/
LTD4 and LTE4 present in clotted and heparinized
blood, as percent of total radioactivity after 60
minutes incubation.
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Fig. 10.Comaparison of 3H-LTC4 metabolism in fresh serum
stored at 4°C for 4 days, -20°C for 7 days and
-70 C for 7 days after 60 minutes incubation.
Procedure was same as described in Figure 8. Data
expressed as percent of total radioactivity at
different elution times corresponding to the
different leukotrienes.
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Fig. 11.Relationship between enzyme concentration and 3HLTC4 metabolism in human serum. Varying amounts of
human serum made up to 1ml using phosphate buffered
saline, were assayed for transpeptidase activity
using procedure described in Fig.8. Data shows
percent of LTC4 metabolized (left y-axis) and
picomoles of LTC4 converted (right y-axis).
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Fig. 12.Relationship between incubation time and3H-LTC4
metabolism in human serum. 0.5 ml serum was made
up to 1 ml using PBS. Assay procedure as described
in Fig 8. Data is expressed as percent LTC4
converted (left y-axis) and picomoles LTC4
converted (right y-axis).
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Fig. 13.Relationship between substrated concentration and
3H-LTC
3H-LTC
4 metabolism. Varying amounts of
4 of
known specific radioactivity were used as
substrate. Assay procedure was as described in
Fig 8. Data expressed as picomoles of LTC4
converted/ml/min. Incubation period was 15
minutes.
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(to 3H-LTD4 and 3H-LTE4) showed a linear relation to time
(Fig. 12).

The conversion of LTC4 also showed a linear

increase with respect to substrate concentration (Fig. 13).
Leukotriene metabolism in mouse serum

Using 3H-LTC4 as a substrate, the profile of LTC4
metabolism was compared in mouse and human serum.

The

results, as shown in Fig. 14, show a great difference.
After a 30 min incubation, with 0.5 ml of serum,

50% of the

radioactivity was in the LTD4 and LTE4 fractions in human
serum, 47% being present as LTD4.

Whereas in mouse serum,

all the radioactivity in the 15% of converted 3H-LTC4 was
present in the region corresponding to the elution time of
LTE4.

A time course study using 3H-LTC4 showed a much higher

activity in human serum than in mouse serum (Fig. 15).

As

this observation suggested a difference in the rate of LTD4
metabolism, metabolism of 3H-LTD4 was compared in human and
mouse sera (Fig. 16).

The mouse serum was seen to have a

much higher activity, 85% of the 3H-LTD4 being converted in
the first 10 minutes of incubation time, while in human
serum, only 17% was converted under identical conditions.
The metabolism of 3H-LTD4 in both human and mouse sera was
linear with relation to time and substrate concentration
(Figs. 16 and 17).

A difference was seen in the rate of

conversion with relation to the concentration of enzyme
(volume of serum) used, as shown in Fig. 18.

Serial

dilution of sera were used in this experiment, because the
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rate of conversion of 3H-LTD'4 was seen to be much faster than
that of 3H-LTC4.

The rate of conversion of 3H-LTD4 did not

decrease with increasing dilutions in human serum.

This

suggested the presence of some factor in the serum that
inhibited the enzyme activity in the undiluted form, or in
lower dilutions.

Heating the sera to 65°C in a water bath

for 30 min decreased the activity in both human and mouse
serum.

The activity in the heated sera of both species was

the same (21%) as shown in Fig. 19.

The effect of heat

inactivated human and mouse serum on unheated human and
mouse serum was studied (Fig. 20,21).

The results show that

while heat inactivated human serum was able to decrease LTD4
conversion in normal human and mouse serum, heat inactivated
mouse serum did not show the same effect.
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Fig. 14.Comparison of profiles of3H-LTC4 metabolism in
human and mouse serum after 30 minutes incubation.
Procedure as described in Fig 8. Data expressed as
percent radioactivity at different elution times.
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Fig 15. Effect of incubation time on3H-LTC4 conversion in
mouse and human serum. 100 ul serum, brought to a
total volume of 250 ul with Hartmann's solution and
at 0.1% Triton X-100, was incubated in the presence
of 160 picomoles3H-LTC4 (22,000 dpms) at 37°C.
Data expressed as percent of LTC4 converted (left y
axis) and picomoles LTC4 converted (right y axis).
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Fig. 16.Comparison of dipeptidase activity in human and
mouse serum. Procedure as described in Fig 15,
except3H-LTD4 was used as substrate. Data
expressed as percent LTD4 converted (left y-axis)
and picomoles LTD4 converted (right y- axis).
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Fig. 17. Relationship between3H-LTD4 conversion and
substrate concentration expressed as picomoles/ml.
Experimental procedure as described in Fig. 16,
except that different substrate concentrations of
varying specific radioactivity were used. Data
expressed as picomoles converted/ml/min.
Incubation period was 15 minutes.
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Fig. 18.Relationship between LTD4 conversion and amount of
serum present. 100 ul of 2-fold serial dilutions
for human and mouse serum we're used. Experimental
procedure as described in Fig. 16. Incubation
period was 15 minutes. Data expressed as percent
LTD4 converted (left y axis) and picomoles LTD4
converted (right y axis).
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Fig. 19.Dipeptidase activity in heat treated and untreated
human and mouse serum after 30 minutes incubation.
The dipeptidase activity was assayed as per
procedure described in Fig 16.
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Fig. 20.Effect of increasing amounts of heated human serum
on the dipeptidase activity in normal human serum
after 30 minutes incubation. Data expressed as
percent conversion (left y axis), as well as
picomoles of LTD4 converted (right y axis).
Different amounts of heat inactivated serum were
added to 100 ul of 1/8 dilution of normal human
serum brought to 250 ul with Hartmann's solution
and 0.1% Triton X-100 and incubated with 160
picomoles3H-LTD4 (22,000 dpms).
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Fig. 21.Comparison of dipeptidase activity in normal human
and mouse serum in presence of heat inactivated
human or mouse serum after 30 minutes incubation.
Procedure as described in Fig 20. Data expressed
as percent LTD4 converted (left y-axis) and
picomoles LTD„ converted (right y-axis).

Leukotriene Metabolism in different animal species

The metabolism of 3H-LTC4 and 3H-LTD4 in human, mouse,
guinea pig and rabbit sera were compared by time course
studies.

No studies were done to compare the conversion of

LTC4 and LTD4 with relation to the volume of serum present,
or substrate concentration.

Fig. 22 and Fig. 23 show the

difference in the profile of 3H-LTC4 and 3H-LTD4 metabolism in
the four species.

Fig. 24 shows the relative amount of 3H-

LTD4 present in the converted 3H-LTC4 in the four species
after specific incubation times.

Fig.25

shows the amount

of LTD4 present as a percent of the total 3H-LTC4
metabolized.

The wide variation of this value in the four

species and the correlation of this value with the
susceptibility to develop anaphylaxis made it necessary to
repeat the experiment.

In the following experiment, in

which fresh serum was used, horse and cow serum and fetal
bovine serum (FBS) were included.

Fig 26

and

Fig. 27 show

the time course of LTC4 and LTD4 conversion in the different
species.

Fig.28 shows the relative amount of3H-LTD4

present, as a percentage of the total converted 3H-LTC4,
after 15, 60 and 90 min incubation.

Fig. 29 shows a

comparison of the relative amounts of a radioactive
metabolite of 3H-LTD4 metabolism, which has not been
identified.

The values mentioned in this experiment are an

average of the results from experiments done in duplicate
(Table II).
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Fig. 22.Comparison of transpeptidase activity in human,
mouse, guinea pig and rabbit serum. Procedure as
described in Fig 15. Data expressed as percent LTC,
converted (left y-axis) and picomoles LTC4
converted (right y-axis).
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Fig. 23.Comparison of dipeptidase activity in human, mouse,
guinea pig and rabbit serum. Procedure as described
in Fig 16. Data expressed as percent LTD4 converted
(left y-axis) and as picomoles LTD4 converted
(right y-axis).
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Fig. 26.3H-LTC4 conversion in 100 ul of horse, cow, fetal
bovine, human, rabbit, mouse, and guinea pig as a
time course study. Procedure as described in Fig
15. Data expressed as per cent LTC4 converted
(left y axis) and picomoles LTC4 converted (right
y axis).
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Fig. 27.Conversion of3H-LTD4 in 100 ul of horse, cow,
fetal bovine, human, rabbit, mouse, and guinea
pig as a time course study. Procedure as
described in Fig 16. Data expressed as per cent
LTD4 converted (left y axis) and picomoles LTD4
converted (right y axis).
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"able II. Duplicate values obtained for percent conversion
of 3H-LTC4 and 3H-LTD4 after varying periods of
incubation in the sera of the different species
tested.

DISCUSSION:

Arachidonic acid metabolites have been associated
with a variety of inflammatory reactions.

Products of the

lipoxygenase pathway of metabolism, the peptidoleukotrienes
(formerly referred to as SRS-A) are important mediators in
immediate hypersensitivity reactions (24,54).

Elevated

levels of peptidoleukotrienes were noticed in bronchial
asthma and are thought to be responsible for the symptoms in
bronchial asthma, which is an immediate hypersensitivity
reaction.

Elevated leukotriene release from lungs of

animals, during experimentally induced anaphylactic
reactions have been reported (18,30,53,62).

The profile of

leukotriene metabolism in different species of animals were
studied to see if a correlation exists between the
leukotriene metabolism profile, and the relative species
susceptibility to develop anaphylaxis.
Using 3H-LTC4 as substrate, supernatant from RBL-1
cells were seen to convert LTC4 to other radioactive
substances, which eluted, during RP-HPLC, at times
corresponding to synthetic LTD4 and LTE4.
3H-LTC ,
4

The conversion of

was enzymatic since it was not seen to take place

in a buffer (Fig. 5).
Lipid extraction and analytical procedures, that gave
satisfactory results with RBL-1 cells, were employed to
60

61

extract the leukotrienes from human serum.

3H-LTC
4

was

metabolized by human serum, with the production of new
radioactive products, which
LTE4.

eluted with synthetic LTD4 and

Conversion of 3H-LTC4 or 3H-LTD4 was not observed in

Hartmann's solution at 37°C, serum at 4°C, or in protein
denatured serum(Fig. 6,7).

The metabolism of 3H-LTC4 in

human serum was dependent on time, amount of enzyme present
(volume of serum) and on the substrate concentration (Fig.
11, 12, 13).

In the time course study (Fig. 8), more

radioactivity was seen
incubation periods.

As

in the LTD4 region with shorter
incubation time increased, the

amount of radioactivity decreased in the LTD4 region and
increased in the LTE4 region, showing that LTC4 was first
converted to LTD4, which was then converted to LTE4.

These

findings are in accordance with the current knowledge about
LTC4 metabolism; that LTC4 is first converted to LTD4 and
that LTD4 is then converted to LTE4 (24,54).
The enzymatic activity in serum was influenced by
storage conditions.

Prolonged storage at temperatures above

-70°C were seen to decrease the conversion of LTD4 to LTE4
(Fig.10).

A difference in LTD4 conversion was also noticed

using heparinized versus clotted blood.

When blood was

heparinized, the LTD4 conversion was the same as in clotted
blood, when assayed immediately; however, when heparinized
blood was stored overnight at 4°C, prior to separation of
plasma, the amount of LTD4 converted was seen to be reduced
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(Fig. 9).

The LTD4 conversion requires

for optimal activity (39,52).

Ca2+, Mg2+, and Mn2+

The presence of substances

like L-cysteine and dithiothreotol, which remove divalent
cations from the medium are known to inhibit the LTD4
conversion (39).

Subsequent addition of these cations at 1

mM concentration was seen to restore the lost activity (39).
Although the anticoagulant effect of heparin is not due to
the removal of Ca2+, it is possible that it is acting as an
inhibitor of LTD4 conversion because it has the property of
activating protease inhibitors, which in turn prevent the
conversion of prothrombin to thrombin (70).
Initially, leukotriene metabolism in serum of normal
Balb-C mouse was compared with that in human serum.

The

profile in normal mouse serum was seen to be very different
from that in humans (Fig.14,15).

After

30

minutes

incubation, 0.5 ml of normal human serum showed 67%
conversions, with 34.6% recovered as LTD4 and
LTE4.

The mouse serum showed only

15.1% as

13.4% conversion, and

all the radioactivity of the metabolized 3H-LTC4 was
recovered as LTE4.

It was presumed from these results, that

the formation of LTD4 must be a much slower process in mouse
than in humans, and that the LTD4 formed was immediately
converted to LTE4.

Subsequent experiments with

3H-LTD
4

as

substrate, showed that the amount of LTE4 formed during LTD4
conversion was 4.2 times more in mouse than in humans
(Fig.16).

These findings correlate with results of
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experiments by Applegreen and Hammarstrom (4), who found
that 20 minutes after intravenous injection of 3H-LTC3 into
mice, the radioactivity was recovered as LTC3 in liver and
other organs.
60 minutes.
tissue.

3H-LTE
3

was detected only in the lung, after

Recovery of 3H-LTD3 was not reported in any

LTC3 has been reported as having similar biological

activity and enzyme specificity as LTC4 (21); therefore the
profile of LTC3 metabolism should reflect that of LTD4.
Since LTD4 is biologically the most potent
peptidoleukotriene, the absence of LTD4 accumulation in
mouse serum, correlates with the reported resistance to the
development of anaphylaxis in the mouse (35,45,69).
The conversion of LTD4 was studied in mouse and human
sera, in the same way as the LTC4 conversion, using
as substrate.

The rate of conversion of LTD4 increased with

time, as well as with
17).

3H-LTD
4

substrate concentration (Fig.16 and

However, the rate of reaction did not decrease in a

linear manner, with increasing dilutions (Fig. 18).

The

rate of conversion increased up to a dilution of 1/8, and
then declined.

This observation implied that the serum

contained another factor, the presence of which was reducing
LTD4 conversion, in the undiluted form.

Initial dilutions

could have diluted the effect of this factor,

leading to an

increase in the LTD4 conversion.
The presence of an inhibitor of LTD4 conversion has
been mentioned briefly, by

Raulf and coworkers in 1985

(51).

They suggested that a rapid decline in LTD4

conversion in supernatant of stimulated RBL-1 cells was
probably due to the presence of inhibitors.

An attempt was

made to study the nature of this "inhibitor" in serum.

The

enzyme activity in the serum was destroyed by immersing
serum in a 65°C water bath for 30 minutes (Fig. 19).

This

temperature was chosen, because temperatures above 65°C
solidify the serum, due to coagulation of serum proteins,
making it unfit for enzyme assay.

Addition of heat

inactivated human serum to unheated human serum was seen to
decrease the LTD4 conversion by the unheated serum, in a
concentration dependent manner (Fig.20).

The effect of heat

inactivated human and mouse serum, on unheated human and
mouse serum, was compared.

The heat inactivated human

serum, seemed to contain larger amounts of the "inhibitory
substance'', as shown by the dramatic reduction of activity
in normal mouse serum (which showed high rate of LTD4
conversion), as compared to the reduction of activity in
human serum.

Heat inactivated mouse serum did not have as

much an inhibitory effect on mouse serum, or on human serum
(Fig.21).

Based on the results of this experiment, human

serum was thought to contain a higher concentration of an
unknown heat stable substance, which decreased the rate of
conversion of LTD4.

This "inhibitory factor", could have

increased the accumulation of 3H-LTD4 in human serum.
Absence, or a less amount of this substance in mouse serum

might contribute to the higher resistance offered by mice to
the development of anaphylaxis.

Further studies, leading

to characterization of this "inhibitory factor" are now in
progress.
The interesting results obtained by comparing human and
mouse serum, with respect to leukotriene metabolism, and the
correlation of these results with the anaphylactic reaction
in these two species, lead us to conduct similar experiments
on sera of other animal species.

Guinea pigs and rabbits

are reported to develop severe anaphylactic reactions (9).
Anaphylactic reactions in horse and cattle have also been
described (8).

In an effort to identify a basis for the

differences in hypersensitivity reactions, 3H-LTC4 and 3HLTD4 were used as substrates to study the profile of
leukotriene metabolism in human, mouse, guinea pig and
rabbit serum.

The profile of LTC4 conversion different in

all four species (Fig. 22).

It was highest in human serum,

32% being converted by 100 ul of serum after 60 min
incubation.
6% and

Rabbit and mouse sera showed a similar profile,

4% being converted after 60 min, while guinea pig

serum showed least activity, 0% LTC4 being converted after
60 min.

LTD4 is the most potent of the peptidoleukotrienes,

with respect to biological activity.

Therefore the relative

amount of LTD4 present as a percent of the total converted
3H-LTC
4

was determined

(Fig. 24 and 25).

Larger amounts

were present in human, guinea pig and rabbit sera, 25, 65

66

and 72% being present respectively.

In the mouse serum,

only 4% of the converted 3H-LTC4 was present as

3H-LTD .
4

The

difference in the relative amount of LTD4 present suggested
a difference in the metabolism of LTD4.

Using 3H-LTD4 as a

substrate, LTD4 metabolism in the four species was compared
(Fig.23).

The mouse serum showed highest activity, which

accounted for the negligible amounts of LTD4 accumulation in
mouse serum. The susceptibility to the development of
anaphylaxis, in the different species described by earlier
workers (9,50), seemed to be related to the rates of
synthesis and metabolism of LTD4; i.e., the lower the rate
of LTD4 synthesis, or the higher the rate of LTD4
conversion, less prone was the animal to develop a severe
anaphylactic reaction.
The above experiment was done using sera stored at
-70°C immediately after collection.

Another experiment was

designed using fresh serum from each species.

In this

experiment, which was done in duplicate, the serum was
placed at 4°C (for 1 hour maximum time) until the assay was
done.

Sera from horse, cow and fetal bovine were also

included.

The mouse serum in this experiment came from

Swiss Webster (SW) mice, whereas in the previous experiment
it was collected from Balb-C mice.
FBS showed maximal activity,

Sera from horse, cow and

more than 50% of LTC4 being

converted in the first 15 min of incubation (Fig.26).
Metabolism in human, rabbit, guinea pig and mouse sera

showed similar patterns as those described above.

However,

there were differences in the relative amounts of LTD4
produced.

The relative amounts of LTD4 present after 15, 60

and 90 min. incubation are shown in Fig. 28.

In mouse

serum, 100% of the converted LTC4 after a 60 min incubation
was seen as LTD4, in contrast to the complete conversion to
LTE4 in the previous experiment.

Nevertheless, only 6.7% of

the 3H-LTC4 was metabolized. Moreover, a high rate of LTD4
conversion was observed in the mouse serum, which could
could lower the LTD4 level as soon as it arises.

A

significant decrease in the LTD4 levels was seen after 90
min.

This difference seen between the two experiments, may

be due to a strain difference.

Since development of

anaphylaxis is thought to be genetically controlled (58), it
could be that a strain to strain difference exists in the
susceptibility to develop anaphylaxis. A strain difference
in asthma models in rats has been reported (37). Experiments
dealing with induction of anaphylaxis in different strains
of mice are necessary to confirm this view.
The addition of 3H-LTC4 to rabbit serum resulted in
the accumulation of a large amount of 3H-LTD4 even after 90
minutes incubation (Fig. 28).

This correlated with the

susceptibility of the animal to develop anaphylaxis.

In the

presence of a high rate of LTC4 conversion, a slower rate of
LTD4 conversion would be expected, in order to maintain high
levels of LTD4 even after 90 minutes incubation with 3H-LTC4.
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Surprisingly, rabbit serum showed a high rate of
conversion (Fig.27).

This observation was different from

that in the previous experiment.

In human serum, a large

amount of LTD4 was present after 60 and 90 min incubation
(Fig.28).

This appeared to result from a high

rate of LTC4

metabolism and a lower rate of conversion of LTD4 to LTE4.
This metabolic profile might maintain a high level of LTD4
for prolonged periods of time.

This pattern of leukotriene

metabolism might, therefore contribute to the prolonged
symptoms of anaphylaxis in humans, ( eg., the symptoms of
bronchial asthma).

The slow rate of metabolism of LTD4

might account for the high amounts of LTD4 in the
supernatant from alveolar macrophages in asthmatics
individuals, as compared to those from normal individuals,
reported by Damon and coworkers (17)..

However,

Schwartzberg and coworkers (56), and Isono and coworkers
(26)

found only LTC4 in the serum during an acute asthmatic

attack in children. These findings suggest that during an
acute asthmatic attack, the metabolism of leukotrienes in
the lung might be different from that in the blood.
The LTC4 conversion as well as the LTD4 conversion
activity in guinea pig serum seemed to be the lowest of all
sera tested (Fig. 26,27).

Although the rate of conversion

of LTC4 was low, the slow rate of LTD4 conversion might be
responsible for accumulation of the converted 3H-LTC4 as
LTD4.

These observations correlate with those of in vivo
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experiments conducted by Keppler et al (30), where LTD4 was
the main metabolite in bile following anaphylactic shock in
the guinea pig.

Clancy and coworkers (15) have reported

LTD4 as the main metabolite in the supernatant of guinea pig
lung tissue after incubation with LTC4.

De Nucci and

coworkers (18) have identified LTD4 as the main metabolite
in perfused lung tissue, after antigen challenge.

Guinea

pig and mouse sera showed a similarity in the profile of
LTC4 metabolism.

3H-

On comparing the relative amounts of LTD4

following 3H-LTC4 metabolism, 100% of the metabolized 3H-LTC4
was recovered as LTD4 after 60 minutes incubation.

However,

the rapid rate of LTD4 conversion in mouse serum brought
about a reduction in the 3H-LTD4 levels after 90 minutes
incubation (Fig 28).

This suggests that LTD4 conversion is

more important than LTC4 conversion in controlling -the
accumulation of LTD4.
Although guinea pig and rabbit sera are similar in the
relative amounts of LTD4 present, the anaphylactic reaction
is different in the two species.

In guinea pig, the

anaphylactic reactions mimic that in humans, and the
respiratory distress is similar to that seen in bronchial
asthma in humans (50).

These symptoms are due to narrowing

of bronchioles due to smooth muscle constriction.

Although

respiratory distress occurs in rabbit, it is not due to
bronchoconstriction, but rather due to constriction of the
pulmonary artery.

This has been shown by experiments in

which a rise in pulmonary arterial pressure was demonstrated
(16).

The pulmonary artery of the rabbit has a more

developed smooth muscle layer, whereas the bronchioles have
less smooth muscle than in the guinea pig.

After fatal

anaphylaxis, a difference in lung pathology supports the
fact that in rabbit, death is due to cardiac failure due to
raised pulmonary arterial pressure, whereas in guinea pig it
is due to bronchoconstriction (50).

For these reasons, the

guinea pig is known to be a better experimental animal model
for bronchial asthma.
In horse and cow serum, both LTC4 and LTD4 conversion
were seen to be high, reaching almost maximal levels after
15 min incubation (Fig.26,27).
3H-LTD
4

Although large amounts of

are formed in the initial stages, these levels

decline rapidly due to increased LTD4 conversion. This
observation correlates with the description of the
anaphylactic reaction in horse and cattle (8), where the
symptoms of respiratory distress develop within 8-15
minutes, and then subside spontaneously.

The horse and cow

serum appeared to be similar to human serum in that
significant amounts of LTD4 were present after 15 min
incubation.

This might be one of the factors responsible

for the similarity in symptoms of anaphylaxis between
humans, horse and cattle (50).
The relative amounts of LTD4 present were expressed
as a percentage of the total converted 3H-LTC4.

The

radioactive substances other than LTD4 were not always
confined to the LTE4 region.

In certain species, as in

horse, and in FBS, an additional radioactive peak was seen
immediately after the elution of LTE4.

The elution time

of

this metabolite did not coincide with that of standard
preparations of LTC4, LTD4, LTE4, N-acetyl LTE4, or LTF4.

The

formation of this unknown substance did not appear to be
related to the rate of LTD4 conversion reaction (Fig 29), as
it was not seen in rabbit and mouse serum which showed high
rate of conversion of LTD4.

Hammarstrom (23) has reported

the presence of eight LTC4 metabolites in the feces of rats
after subcutaneous injection of
have not yet been identified.

3H-LTC .
4

Several of these

Until this substance has been

identified, and its biological activity assessed, it cannot
be concluded if the formation of this substance enhances or
decreases the symptoms in an anaphylactic reaction.
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